Citius Oncology, Inc.

As of June 30, 2026, Citius Oncology, Inc. carries a market capitalization of 68.75M, placing it among publicly traded companies globally. Its enterprise value stands at 62.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Citius Oncology, Inc.'s next confirmed earnings release is scheduled for December 17, 2026.

As of June 30, 2026, Citius Oncology, Inc. has 105.76M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 8.61, and the price-to-book ratio stands at 1.70.

These figures are as of June 30, 2026. The EV/Sales ratio of 8.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 62.40M versus a market cap of 68.75M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Citius Oncology, Inc. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.28, indicating elevated leverage, while an interest coverage ratio of -78.74 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Citius Oncology, Inc. posted a negative return on equity (ROE) of -126.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -45.20, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2026, Citius Oncology, Inc. recorded 189,923.00 in income tax expense. The company reported a pretax loss of -45.87M and -46.06M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Citius Oncology, Inc.'s stock has declined approximately 57.61% over the past 52 weeks. The 50-day moving average sits at 0.86, while the 200-day moving average is 0.85.

Over the twelve months ended June 30, 2026, Citius Oncology, Inc. generated 7.11M in revenue and converted that into -46.06M in net income, yielding earnings per share of -0.49. EBITDA reached -43.10M, while operating income came in at -47.29M.

As of June 30, 2026, Citius Oncology, Inc. holds 16.56M in cash and equivalents against 10.21M in total debt, resulting in a net debt position of -6.35M. Total book value stands at 40.38M, with working capital of -16.08M providing operational flexibility.

Citius Oncology, Inc. produced -19.39M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.00M in capital expenditures, free cash flow totaled -26.39M - equivalent to -0.28 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -665.63 and net profit margin of -648.32 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -43.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Citius Oncology, Inc. has an Altman Z-Score of -6.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.